Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1124146

registered interest
date	01/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 April 2019 to Question 245610, how many forms of cancer have no maintenance drug available at any stage in the treatment plan.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	249828
answer	answer is ministerial correction date of answer 08/05/2019 answer text <p>The information requested is not available.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 08/05/2019 13:54:02 answering member 4455 label Biography information for Seema Kennedy
tabling member	394 label Biography information for Mr Clive Betts

1121970

registered interest
date	18/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 15 April 2019 to Question 242692 on Cancer: Drugs, what steps the Government is taking to give timely NICE and NHS approval to enable access to maintenance medication for people with cancer.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	245610
answer	answer is ministerial correction date of answer 25/04/2019 answer text <p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources. NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.</p><p>The Government wants patients with cancer to be able to benefit from rapid access to effective new drugs, including for maintenance treatment. Under arrangements introduced in 2016, NICE now develops technology appraisal guidance for the NHS on all new cancer drugs. Wherever possible, NICE aims to issue draft guidance on new cancer drugs before licensing and to publish final guidance within 90 days of licensing.</p><p>Funding is available through the Cancer Drugs Fund from the point at which NICE draft recommendations are published, or if the drug is not currently licensed, from the point of licensing. This ensures patients are able to benefit from effective new cancer drugs as quickly as possible.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 25/04/2019 14:05:35 answering member 4455 label Biography information for Seema Kennedy
tabling member	394 label Biography information for Mr Clive Betts

1110551

registered interest
date	09/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps is the Government taking to ensure timely access to maintenance medication for people with cancer.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	242692
answer	answer is ministerial correction date of answer 15/04/2019 answer text <p>The Department fully understands that maintaining access to cancer medication is vitally important to many people in this country.</p><p> </p><p>There is already a team within the Department that deals with medicine supply issues arising both in the community and hospitals. We have well established procedures to deal with medicine shortages, from whatever cause, and work closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when they do arise.</p><p> </p><p>If we are aware of issues with cancer medications we work with national clinical experts to advise on management plans and ensure that appropriate information is provided to the National Health Service and specialist patient groups.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 15/04/2019 12:58:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	394 label Biography information for Mr Clive Betts

1092072

registered interest
date	20/03/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to prioritise patients with (a) terminal cancer and (b) cancer for the receipt of drugs in the event of medicine shortages due to the UK leaving the EU (i) without an agreement and (ii) with an agreement under which the medicine supply is restricted.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	234769
answer	answer is ministerial correction date of answer 25/03/2019 answer text <p>Leaving the European Union with a deal remains the Government’s top priority. However, as a responsible Government we must plan for every possible outcome including ‘no deal’. The Department has published guidance to industry and the health and care system to allow them to make informed plans and preparations. This is available on GOV.UK.</p><p> </p><p>The Government has been working closely with industry to ensure the supply of medicines, including those for cancer patients, can continue uninterrupted in the event of a ‘no deal’ EU exit, including building stockpiles, providing additional warehousing space and buying freight capacity on alternative ferry routes.</p><p> </p><p>In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the United Kingdom that come from, or via, the EU/European Economic Area asking them to ensure a minimum of six weeks’ additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019 in the event of a ‘no deal’ EU exit.</p><p> </p><p>The Department has put in place a multi-layered approach to minimise any supply disruption, which includes securing, via the Department for Transport, additional roll on roll off freight capacity away from the short straits crossings to Dover and Folkestone for goods to continue to come into the UK from 29 March. In addition to asking industry to build up stockpiles in the UK ahead of 29 March we have bought extra warehouse space for the additional stock to be held in. We are supporting companies in booking space on aircraft for products which require an immediate shipment due to short shelf-life or specific storage conditions. We have also made changes to, or clarifications of, certain regulatory requirements so that companies can continue to sell their products in the UK even if we have no deal. Finally, we are strengthening the processes and resources used to deal with shortages in the event that they do occur.</p><p> </p><p>We are confident that, if everyone does what they need to do, the supply of medicines and medical products will be uninterrupted.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 25/03/2019 16:06:45 answering member 1585 label Biography information for Stephen Hammond
tabling member	4621 label Biography information for Darren Jones

985621

registered interest
date	11/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will take steps as part of the ongoing negotiations for the next Pharmaceutical Price Regulation Scheme to ensure that increasing the number of combination treatments for cancer can be considered cost-effective and made available for patients.
tabling member constituency	Westmorland and Lonsdale
tabling member printed	Tim Farron
uin	178268
answer	answer is ministerial correction date of answer 17/10/2018 answer text <p>The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative cancer treatments and technologies at a price the National Health Service can afford. Discussions on a branded medicines voluntary agreement for 2019 onwards are ongoing and are constructive.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/10/2018 13:54:42 answering member 4067 label Biography information for Steve Brine
tabling member	1591 label Biography information for Tim Farron

851006

registered interest
date	27/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with his counterpart in the Northern Ireland Government on the availability of drugs to treat cancer.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	130201
answer	answer is ministerial correction date of answer 07/03/2018 answer text <p>No such discussions have taken place.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 07/03/2018 10:28:29 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

788523

registered interest
date	13/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to ensure that the NHS receives a fair price for medicines that are developed from monoclonal antibodies.
tabling member constituency	Stockton South
tabling member printed	Dr Paul Williams
uin	112474
answer	answer is ministerial correction date of answer 21/11/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) appraises new medicines for the value they offer to the National Health Service. Products that receive a positive appraisal from NICE are required to be funded by the NHS within three months of final guidance. The Pharmaceutical Price Regulation Scheme 2014 makes provisions for manufacturers and sponsors to submit proposals for patient access schemes (PAS) to the Department as part of NICE appraisal. These schemes involve innovative pricing agreements designed to improve cost effectiveness and facilitate patient access to specific drugs or other technologies and many monoclonal antibodies have PAS in place.</p><p>For monoclonal antibodies that are licensed to treat cancer the Cancer Drugs Fund (CDF) is a source of funding in England, which provides patients with faster access to the most promising new cancer treatments, helps to ensure more value for money for taxpayers and offers pharmaceutical companies (who price their products responsibly) a new fast-track route to NHS funding. The CDF process includes the option for NHS England to hold individual commercial negotiations with pharmaceutical companies to ensure a fair price is agreed upon for cancer treatments.</p><p>Where appropriate NHS England’s Commercial Medicines Unit will use competitive tenders to obtain value for money pricing for monoclonal antibody based medicines used by hospitals.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/11/2017 17:42:24 answering member 4067 label Biography information for Steve Brine
tabling member	4666 label Biography information for Dr Paul Williams

720509

registered interest
date	13/04/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that existing and cost-effective drugs which have been shown to be effective in reducing the risk of recurrence and spread of incurable cancer are repurposed as quickly as possible.
tabling member constituency	Cumbernauld, Kilsyth and Kirkintilloch East
tabling member printed	Stuart C. McDonald
uin	70880
answer	answer is ministerial correction date of answer 24/04/2017 answer text <p>The Government is working with a range of organisations, including the Association of Medical Research Charities, to ensure that robust evidence showing new uses for existing drugs can be brought more systematically into clinical practice to benefit patients.</p><p> </p><p>Significant progress has been made in designing a ‘drug re-purposing pathway’ to help the charities and others to navigate a route through the National Health Service so that they can see how research can be shared at a national level and then picked up locally where it can reach the patient. Work on this is continuing.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 24/04/2017 17:06:50 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4393 label Biography information for Stuart C McDonald

706129

registered interest
date	28/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 3 February 2017 to Question 61825, what estimate his Department has made of the number of deaths that may arise from a lack of availability of bisphosphonates between now and that guidance being published in July 2018.
tabling member constituency	Carshalton and Wallington
tabling member printed	Tom Brake
uin	65858
answer	answer is ministerial correction date of answer 07/03/2017 answer text <p>We have made no such assessment. There is no reason why bisphosphonates should not be prescribed now for the prevention of secondary breast cancer where prescribers assess they are the right treatment for their patients. National prescribing arrangements allow for bisphosphonates to be prescribed for this indication and, in the absence of National Institute for Health and Care Excellence guidance, decisions about the funding and prescribing of individual treatments should be made by National Health Service commissioners and clinicians based on an assessment of the available evidence.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 07/03/2017 11:02:44 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	151 label Biography information for Tom Brake

682343

registered interest
date	31/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects NICE to conclude deliberations on (a) Crizotinib, (b) Pemetrexed, (c) Cetuximab, (d) Dasatinib, (e) Sornfenib, (f) Ibrutinib, (g) Cabazitaxel, (h) Brentuximab, (i) Radium 223 and (j) Trastuzumab Emtansine; what estimate he has made of the cost to the NHS of providing each of these drugs for a 12 month trial period; and what estimate he has made of the period; what estimate he has made of the number of people likely to be prescribed each of these drugs on the NHS in the 12 months following any approval by NICE.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	62519
answer	answer is ministerial correction date of answer 09/02/2017 answer text <p>The information requested is provided in the attached table.</p> answering member constituency Oxford West and Abingdon answering member printed Nicola Blackwood question first answered 09/02/2017 13:31:44 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name PQ62519 attached document.docx title PQ62519 attached document
tabling member	1521 label Biography information for Mrs Sharon Hodgson